KRAS and cancer: Eleven of 12 cancers with KRAS, NRAS, or BRAF activating mutations in TP53 wild-type background that could be classified into molecular subgroups were LOH-low, consistent with the observation that low grade and mesonephric-like histologies are not driven by HRD49.